Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at Goldman Sachs started coverage on Enliven Therapeutics, Inc. (NASDAQ:ELVN) with a Buy rating and a $37.00 price target, implying a rise of about 60% from the current levels. The firm's confidence in the stock stems from favorable Phase 1 data for the company's chronic myeloid leukemia (CML) solution.
The investment bank noted that ELVN-001's sustained efficacy data, presented during the European Hematology Association meeting, highlighted a 47% overall cumulative major molecular response (MMR) rate by 24 weeks and a 41% response in tyrosine kinase inhibitor (TKI)-resistant patients. These results surpassed the fourth-generation Scemblix by Novartis (SIX:NOVN) figures, with a difference of 10% and 32%, respectively.
A biologist in a laboratory examining a microscope for small molecule inhibitors.
The company is all set to launch a Phase 3 trial in 2026, which in itself is a $3 billion opportunity. If we look at the three-year return, Enliven Therapeutics, Inc. (NASDAQ:ELVN) exhibited a return of a whopping 1,980.18% in contrast to the 64.53% return by the market. Calling this simply an 'amazing' performance would be an understatement.
Enliven Therapeutics, Inc. (NASDAQ:ELVN), headquartered in Boulder, Colorado, is a clinical-stage biopharmaceutical company. The company focuses on the recognition and development of small-molecule inhibitors to assist people living with cancer, improving survival and overall well-being.
While we acknowledge the potential of ELVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Investors should consider this growth stock… it's SpaceX's competition
Rocket Lab (NASDAQ:RKLB) is a US-listed growth stock that gives investors rare access to the commercial space sector. As a vertically integrated launch and space systems provider, Rocket Lab is often compared to SpaceX in its ambition and capabilities. But there's one crucial difference: you can actually buy shares in Rocket Lab, while SpaceX remains private. Rocket Lab delivers launch services, builds small and medium-class rockets, and manufactures spacecraft components for a range of commercial, government, and defense customers. With rapid revenue growth, an impressive order book, and expansion into new markets, Rocket Lab offers public market investors a way to participate in the booming space economy. It targets many of the same opportunities as its more famous, privately held peer. Rocket Lab and SpaceX operate in the same commercial space sector but differ significantly in scale, maturity, and valuation. Rocket Lab's market cap is currently $12.85bn, with trailing 12 months (TTM) revenue of approximately $460m. Despite strong growth — revenue nearly doubled from $240m in 2023 — Rocket Lab remains a smaller, earlier-stage player focused on small to medium launch vehicles and spacecraft manufacturing. Its valuation multiples are extremely high, with a forward price-to-sales ratio of 22.3 times, reflecting investor optimism. SpaceX, by contrast, is a far more mature private company valued at about $350bn. It's projected to generate $15.5bn in revenue in 2025. This is driven by its dominant Falcon 9 launch services and rapidly growing Starlink satellite internet business. SpaceX's valuation implies roughly a 22.5 times multiple on forward revenue. This is broadly in line with Rocket Lab. Focusing on Rocket Lab, the company is projected to deliver rapid revenue growth over the next several years, with estimates rising from $573m in 2025 to $889 in 2026, $1.2bn in 2027, and $1.69bn in 2028. This represents annual growth rates consistently above 30%, and even a jump of nearly 77% in 2030. However, the number of analysts providing forecasts declines sharply after 2027, dropping from 11–14 analysts in the near term to just two or one by 2028 and 2030. The one analyst projecting as far as 2030 sees $4bn in revenue for the year. I had the chance to buy Rocket Lab shares at $15 just two months ago. I missed out as unfortunately my attention had been diverted elsewhere. However, I found another entry point. And personally, I see this as an investment to hold for a very long period. The space industry is still in its early innings, with enormous potential as satellite launches, lunar missions, and in-orbit services become increasingly mainstream. And like any investment, there are risks. Rocket Lab remains loss-making. It's expected to turn a profit in 2026, when it will trade at 620 times earnings. And while this moderates to 140 times in 2027, it's still expensive and introduces plenty of execution risk. However, I certainly believe UK investors should consider this one. It could be a real winner going forward. The post Investors should consider this growth stock… it's SpaceX's competition appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool James Fox has positions in Rocket Lab. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Sign in to access your portfolio
Business Upturn
an hour ago
- Business Upturn
Axiom Intelligence Acquisition Corp 1 Announces Completion of $200 Million Initial Public Offering
New York, New York, June 20, 2025 (GLOBE NEWSWIRE) — Axiom Intelligence Acquisition Corp 1 (NASDAQ:AXINU) (the 'Company') today announced the closing of its initial public offering of 20,000,000 units, which includes 2,500,000 units sold pursuant to the partial exercise of the underwriters' over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $200,000,000. The Company's units commenced trading on the Nasdaq Global Market ('Nasdaq') under the symbol 'AXINU' on June 18, 2025. Each unit issued in the offering consists of one Class A ordinary share of the Company and one right to receive one tenth (1/10) of one Class A ordinary share upon the consummation of the Company's initial business combination. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on Nasdaq under the symbols 'AXIN' and 'AXINR,' respectively. The Company is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any stage of its corporate evolution or in any industry or sector, the Company intends to focus its initial search on companies in the European infrastructure industry. The Company's management team is led by Richard Dodd, its Executive Chairman, Douglas Ward, its Chief Executive Officer, Daniel Mamadou-Blanco, its President, Robert Dilling, its Chief Financial Officer, and Chris Ackermann, its Chief Operating Officer. Dr. Claire Handby, Steven Leighton and Christopher Ellis are the Company's independent directors and Sankalp Shangari and Wendy Li are its senior advisers. Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC, acted as the lead book-running manager for the offering. Seaport Global Securities LLC acted as joint book-runner. A registration statement relating to the units and the underlying securities was declared effective by the Securities and Exchange Commission on June 17, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering was made only by means of a prospectus, copies of which may be obtained from Cohen & Company Capital Markets, 3 Columbus Circle, 24th Floor, New York, NY 10019, Attention: Prospectus Department, or by email at: [email protected]. Copies of the registration statement can be accessed for free through the SEC's website at Forward-Looking Statements This press release contains statements that constitute 'forward-looking statements,' including with respect to the anticipated use of the net proceeds of the offering and the Company's search for an initial business combination. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and final prospectus for the offering filed with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law. Contact Information: Axiom Intelligence Acquisition Corp 1Richard Dodd, Executive Chairman / Doug Ward, Chief Executive Officer [email protected] +44 20 3973 7928
Yahoo
an hour ago
- Yahoo
Here are 10 stocks Goldman Sachs expects to be winners after a wild first half for the market
Goldman Sachs just updated one of its stock baskets with its picks for the highest risk-adjusted returns. The basket has outperformed the S&P 500 so far this year, gaining 3% year-to-date. The S&P 500's overall risk-adjusted return has been lower than usual so far this year, strategists said. It's been a volatile year for stock traders, but there are a handful of new winners in the S&P 500 that could be poised for big gains over the next 12 months, according to Goldman Sachs. In a note to clients on Friday, the bank said it updated its Sharpe Ratio basket, a list of 50 stocks with the highest expected risk-adjusted returns. So far, the basket has gained 3% year-to-date, edging past the S&P 500's 1.7% gain. The S&P 500's overall risk-adjusted return has been "lower than usual" so far in 2025, the strategists said, pointing to increased volatility and lower-than-average returns stemming from fears around tariffs. The bank rebalanced its portfolio by choosing stocks with a high prospective Sharpe Ratio, a gauge for risk-adjusted returns calculated by dividing a percentage return to a stock's consensus 12-month price target by its six-month option-implied volatility. "Currently, the median S&P 500 stock is expected to post an 11% return to its 12-month consensus price target with a 6-month implied volatility of 28, yielding a prospective risk-adjusted return of 0.4," the bank wrote. Here are the top 10 newest additions to Goldman's Sharpe basket. Ticker: MRNA Return to consensus price target: 88% Expected return over implied volatility: 1.3 Ticker: VTRS Return to consensus price target: 61% Expected return over implied volatility: 1.5 Ticker: ENPH Return from consensus price target: 45% Expected return over implied volatility: 0.6 Ticker: PCG Return to consensus price target: 45% Expected return over implied volatility: 1.1 Ticker: TMO Return to consensus price target: 42% Expected return over implied volatility: 1.2 Ticker: FI Return to consensus price target: 37% Expected return over implied volatility: 1.2 Ticker: COO Return to consensus price target: 37% Expected return over implied volatility: 1.2 Ticker: CRM Return to consensus price target: 37% Expected return over implied volatility: 1.1 Ticker: LEN Return to consensus price target: 34% Expected return over implied volatility: 0.9 Ticker: EPAM Return to consensus price target: 33% Expected return over implied volatility: 0.8 Read the original article on Business Insider
